Latest news with #K1
Scottish Sun
25-05-2025
- Health
- Scottish Sun
From gummies to sprays – we test three vitamin supplements for fussy kids
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WANT to give your fussy kids vitamins to make up for them refusing fruit and veg? You're not alone. About 16 per cent of youngsters take supplements. 4 Give your fussy kids vitamins to make up for them refusing fruit and veg But a new report shows some gummies contain more sugar than kids' favourite Haribo sweets. Today I look at ways to get vitamins into your children without dosing them up on sugar too . . . Gummies 4 Bassetts makes various kids' vitamins Credit: Bassetts BASSETTS makes various kids' vitamins. Its Soft & Chewy Multivitamin gummies in summer berries flavour are for ages 12 to 18 – perfect for those that may not be eating their five a day. They contain nutrients to support teenagers' health, including vitamins C and D to aid the immune system, and B2 and B12 to help reduce tiredness and fatigue. Although these don't contain sugar they do have sweeteners – maltitol, sorbitol and sucralose – which are said to be safe for children. These aren't for vegetarians as they contain gelatine which comes from cows but they taste great with a berry flavour. Summer Berries gummies, 30 for £7. Powder 4 Junior Revive is a supplement that contains 12 vitamins and six minerals Credit: Supplied JUNIOR REVIVE is a supplement that contains 12 vitamins and six minerals. It has four fruit and vegetable powders, beta glucans (a fibre that can stimulate the immune system), live friendly bacteria (for gut health) and choline (a nutrient similar to B vitamins). Top 5 Vitamins for Beautiful Hair All these support a child's immunity, energy and mental performance. This is designed for children over four and up to 12 and comes in little sachets. You simply add one sachet to 100ml of water or into a smoothie, yoghurt or juice. I love the fact this is unflavoured and is a great all-rounder. Because it has no flavour there are no sweeteners either. I love this. From £14.92 for a box of 20 or 75p a sachet. Spray 4 Oral sprays feature tiny droplets that absorb quickly into your mouth Credit: Supplied ORAL sprays feature tiny droplets that absorb quickly into your mouth and then directly into the bloodstream, bypassing the digestive system. BetterYou Multivitamin kids' oral spray has 14 essential vitamins and is free from sugar, gluten artificial colours and additives. It contains the full spectrum of B vitamins, including folic acid, combined with vitamin A, vitamin C, K1 and vitamin D. Suitable for youngsters aged over one year. Despite having no sugar this 'chocolate and marshmallow' flavour (which my kid loved) is very, very sweet. This is due to the sweetener xylitol which is generally considered safe for children when used in moderation and comes from plant fibres. The 25ml bottle contains a 32-day supply and you need to have four sprays a day. Starts at £8.46.
The Irish Sun
25-05-2025
- Health
- The Irish Sun
From gummies to sprays – we test three vitamin supplements for fussy kids
WANT to give your fussy kids vitamins to make up for them refusing fruit and veg? You're not alone. About 16 per cent of youngsters take supplements. Advertisement 4 Give your fussy kids vitamins to make up for them refusing fruit and veg But a new report shows some gummies contain more sugar than kids' favourite Haribo sweets. Today I look at ways to get vitamins into your children without dosing them up on sugar too . . . Gummies 4 Bassetts makes various kids' vitamins Credit: Bassetts BASSETTS makes various kids' vitamins. Its Soft & Chewy Multivitamin gummies in summer berries flavour are for ages 12 to 18 – perfect for those that may not be eating their five a day. Advertisement They contain nutrients to support teenagers' health, including vitamins C and D to aid the immune system, and B2 and B12 to help reduce tiredness and fatigue. Although these don't contain sugar they do have sweeteners – maltitol, sorbitol and sucralose – which are said to be safe for children. These aren't for vegetarians as they contain gelatine which comes from cows but they taste great with a berry flavour. Summer Berries gummies, 30 for £7. Advertisement Most read in Health Powder 4 Junior Revive is a supplement that contains 12 vitamins and six minerals Credit: Supplied JUNIOR REVIVE is a supplement that contains 12 vitamins and six minerals. It has four fruit and vegetable powders, beta glucans (a fibre that can stimulate the immune system), live friendly bacteria (for gut health) and choline (a nutrient similar to B vitamins). Top 5 Vitamins for Beautiful Hair All these support a child's immunity, energy and mental performance. Advertisement This is designed for children over four and up to 12 and comes in little sachets. You simply add one sachet to 100ml of water or into a smoothie, yoghurt or juice. I love the fact this is unflavoured and is a great all-rounder. Because it has no flavour there are no sweeteners either. I love this. From £14.92 for a box of 20 or 75p a sachet. Advertisement Spray 4 Oral sprays feature tiny droplets that absorb quickly into your mouth Credit: Supplied ORAL sprays feature tiny droplets that absorb quickly into your mouth and then directly into the bloodstream, bypassing the digestive system. BetterYou Multivitamin kids' oral spray has 14 essential vitamins and is free from sugar, gluten artificial colours and additives. It contains the full spectrum of B vitamins, including folic acid, combined with vitamin A, vitamin C, K1 and vitamin D. Suitable for youngsters aged over one year. Advertisement Despite having no sugar this 'chocolate and marshmallow' flavour (which my kid loved) is very, very sweet. This is due to the sweetener xylitol which is generally considered safe for children when used in moderation and comes from plant fibres. Read more on the Irish Sun The 25ml bottle contains a 32-day supply and you need to have four sprays a day. Starts at £8.46. Advertisement
Los Angeles Times
14-05-2025
- Business
- Los Angeles Times
Small Language Models and Proprietary Data Represent the Future of Enterprise AI
At the recent Milken Global Conference, K1's Neil Malik shared why K1's focus has always been on acquiring software businesses that are the ultimate system of record for their enterprise customers. As leaders across finance, technology, and policy gathered last week in Los Angeles for the Milken Institute Global Conference, artificial intelligence remained a defining topic – with the dialogue shifting from future potential to real deployment across global industries. We spoke with Neil Malik, Founder and CEO of K1, about how the firm is navigating this shift by investing in companies that sit at the intersection of proprietary data and AI-driven automation. The enterprise software industry is undergoing a seismic transformation – and artificial intelligence is at the center of it. While many companies are experimenting with AI, the real winners will be those who integrate AI into mission-critical systems of record: platforms that hold proprietary, often regulated, data accessible only through their applications. These systems create a durable competitive advantage. For Neil, this is more than just a thesis – it has been the foundation of K1's investment strategy since the firm's inception. 'Our companies are the systems of record for highly sensitive and, oftentimes, regulated data – and that's what makes their AI capabilities so powerful,' Neil says. 'When you pair proprietary, structured data with mission-critical applications, you can build AI and automation layers on top that aren't just impressive – they're trusted, targeted, and deeply embedded in the customer's daily operations.' By investing in AI-powered enterprise software, K1 is not just adapting to industry change – it's helping shape the next generation of category leaders. 'Our portfolio companies are really benefiting from the recognition of the value of artificial intelligence, and large enterprise customers are now rushing to buy more modern platforms like the ones we offer. As a result, many of our companies are disrupting legacy incumbents.' AI adoption in the enterprise is accelerating, but as Neil noted, K1's portfolio companies are enabling Fortune 500 and Global 2000 businesses to keep pace. Built within the last 10–15 years, these companies are cloud-native by design, allowing them to adopt and deploy AI faster than many of their legacy competitors. The data in these platforms is typically highly sensitive, difficult to move, and not suitable for public AI models. As a result, the embedded applications and automation built within these platforms are increasingly sought after to help unlock insights and value from that data. Some of K1's portfolio companies are seeing near 100% year-over-year growth in bookings tied to AI-powered products – a clear sign that AI is driving topline results, not just operational efficiency. Vertical AI isn't built on prompts – it's built on proprietary data. That's exactly where K1's portfolio companies are focused – embedding AI on top of the critical data. Across the K1 portfolio, companies are advancing AI capabilities, particularly around agentic AI use cases that drive workflow automation and measurable productivity gains for customers. Because many of these companies serve verticals such as financial services, legal, healthcare, and education, they are uniquely positioned to build domain-specific models. These models are trained on clean, compliant, and non-public data – deeply integrated with business-critical processes. For private equity firms focused on enterprise software, the landscape is changing. 'We've had an opportunity to see multiple cycles in the economy over the last 30 years. Our job is to seek predictable and repeatable ways of generating alpha for our clients in and out of these cycles – and we believe advancements in artificial intelligence allow us to accelerate our ability to do just that.' That disciplined approach has helped K1 invest in over 250 software companies, making it one of the largest – and fastest growing – investors in small-cap enterprise software globally. According to sources close to the firm, K1 has had a record 18 months of liquidity, with 13 liquidity events in that time, including two in the last month. Notable recent exits include GoCanvas (acquired by Nemetschek, FRA:NEM), Irwin (acquired by FactSet, NYSE:FDS), Axcient (acquired by ConnectWise, a Thoma Bravo company), and AppLearn (acquired by Nexthink). Importantly, K1's strategy has performed well even in a challenged exit environment. The firm has historically not relied on IPOs to generate returns – instead driving liquidity through strategic sales, even when public markets are quiet. As many in the industry grapple with distribution shortfalls, K1 expects to deliver additional realizations in 2025. And while tariffs and geopolitical uncertainty have slowed decision-making in some sectors, these factors have not negatively impacted K1's portfolio or deal velocity to date – a testament to the mission-critical nature of the software companies the firm backs. K1 is now preparing to begin deploying additional capital, with over $1 billion of opportunities currently in exclusivity.
Business Wire
21-04-2025
- Business
- Business Wire
HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads
HANGZHOU, China--(BUSINESS WIRE)--HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer and other diseases, announced today it has filed two investigational new drug (IND) applications (HF158K1 and HFK2) with China's National Medical Products Administration for immunoliposomes carrying different cancer killing payloads. The planned clinical study will evaluate the two drugs' safety and pharmacokinetics as well as their combined therapeutic effects in solid tumor patients refractory to prior treatments. The new technology behind HighField's immunoliposomes may offer greater safety and efficacy than existing antibody drug conjugates (ADCs) Share The two drugs are derived from HighField's proprietary ADCplex TM platform, containing chemotherapy payloads inhibiting Topoisomerase I and Topoisomerase II activities respectively. HF158K1 (K1) and HFK2 (K2) are both fitted with HER2 antibodies for binding to cancer cell surface HER2 receptors in both HER2 high and low tumors. K1 is being evaluated as a monotherapy in an ongoing Phase 1 trial in the US (NCT05861895). The planned Phase 1 open label, dose escalation trial of K1 and K2 in China will evaluate the safety and pharmacokinetics of K1 as a monotherapy and preliminary efficacy in combination with K2. HighField CEO and Scientific Founder Yuhong Xu, Ph.D., explained, 'The antibody-drug-conjugate (ADC) drugs are designed based on a great concept. Their specificity and efficacy in cell culture models are always perfect. However, in patients, the process of ADC tumor penetration, especially intracellular payload release inside cancer cells, is profoundly nonlinear. Therefore, increasing the dose may not lead to improved efficacy, but only increased toxicity.' Dr. Xu observed, 'Upon modeling the tumor penetration and intracellular delivery process, we came up with the 'golf cart' approach. The liposomes 'escort' the payloads in a more efficient way than ADCs so there is a close to linear dose vs. intracellular delivery correlation. In this case, we can even combine two kinds of immunoliposomes carrying two different payloads and expect higher efficacy and low toxicity.' Preclinical efficacy studies in mouse tumor models showed greater efficacy from K1, K2 and the two combined than marketed ADCs with the same HER2 target. In addition, the efficacy to maximum tolerant dose (MTD) therapeutic windows are wider. About HighField Biopharmaceuticals HighField is a clinical stage company focused on novel applications of liposome constructs directed to immuno-oncology and gene therapy. HighField's lead products in clinical trials are K1, derived from its ADCplex TM platform, followed by HF50, derived from its TCEplex TM platform. The company's pipeline also includes K16, a drug encapsulated immune modulating liposome targeting myeloid-derived suppressor cells in clinical trials for refractory cancers; and HFG1, derived from its tLNPplex™ platform, for mRNA expression of a GLP-1R agonist for weight loss and diabetes. For more information visit
Yahoo
12-03-2025
- Automotive
- Yahoo
Porsche Says It Might Build a New Gas-Powered SUV by 2030
is considering adding an SUV to its lineup to slot alongside the and the Cayenne's soon-to-be trio of powertrain options. Porsche says the new model would feature both gasoline-only and hybrid powertrains. It won't be here anytime soon, though, as the automaker says it could launch closer to 2030. Porsche says its lineup could expand to include another SUV by the end of the decade. And no, it's not the Cayenne EV slated to launch later this year. Heck, it won't even be an EV. Surprisingly, for something that hasn't even been officially announced yet, Porsche says this mysterious new model would feature gasoline-only and hybrid powertrains but not an electric one. The news was revealed as part of Porsche's annual financial outlook meeting, where the automaker hinted that it's considering a new SUV. "... the sports-car manufacturer is currently evaluating an independent model line in the SUV segment with combustion and hybrid powertrains," Porsche said in a release. When, or if, the new model arrives, Porsche's lineup will include an electric-only Macan; options for pure-combustion, hybrid, and battery-electric Cayennes; and combustion and hybrid options for the new model. Unfortunately, the company didn't feel the need to tell us how large the new SUV will be. It could be the three-row K1 model that Porsche announced in 2022, or it could be a different model entirely. It'll likely be a while before we learn anything concrete about the potential new SUV. According to Porsche, if it does decide to bring the new model to market, it won't do so until closer to 2030. You Might Also Like Car and Driver's 10 Best Cars through the Decades How to Buy or Lease a New Car Lightning Lap Legends: Chevrolet Camaro vs. Ford Mustang!
